Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing a WEE1 inhibitor for ovarian cancer treatment, has announced inducement grants under its 2022 Employment Inducement Incentive Award Plan. The company granted stock options for 381,000 shares to six new employees.
The options, priced at $1.72 per share, will vest over four years with 25% vesting in the first year and the remaining 75% vesting monthly over three years. These grants, approved by the Compensation Committee, comply with Nasdaq Listing Rule 5635(c)(4) and are designed to attract new talent to the company.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), una societ脿 biofarmaceutica in fase clinica focalizzata sullo sviluppo di un inibitore WEE1 per il trattamento del tumore ovarico, ha annunciato concessioni di incentivi ai sensi del suo 2022 Employment Inducement Incentive Award Plan. L鈥檃zienda ha assegnato opzioni su 381.000 azioni a sei nuovi dipendenti.
Le opzioni, con prezzo di esercizio di $1,72 per azione, matureranno in quattro anni: il 25% matura nel primo anno e il restante 75% matura mensilmente nei tre anni successivi. Le assegnazioni, approvate dal Compensation Committee e conformi alla Nasdaq Listing Rule 5635(c)(4), sono pensate per attrarre nuovi talenti.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), una compa帽铆a biofarmac茅utica en fase cl铆nica centrada en desarrollar un inhibidor de WEE1 para el tratamiento del c谩ncer de ovario, ha anunciado concesiones de incentivos seg煤n su 2022 Employment Inducement Incentive Award Plan. La empresa otorg贸 opciones sobre 381.000 acciones a seis nuevos empleados.
Las opciones, con un precio de ejercicio de $1,72 por acci贸n, se consolidar谩n durante cuatro a帽os: el 25% se consolida en el primer a帽o y el 75% restante se consolida mensualmente durante los tres a帽os siguientes. Estas concesiones, aprobadas por el Comit茅 de Compensaci贸n y conformes a la Nasdaq Listing Rule 5635(c)(4), est谩n dise帽adas para atraer nuevo talento.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), 雮滌唽鞎� 旃橂毳� 鞙勴暅 WEE1 鞏奠牅鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎届偓搿滌劀, 2022 Employment Inducement Incentive Award Plan鞐� 霐半ジ 鞙犾澑 氤挫儊(Inducement grants)鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 鞁犼窚 歆侅洂 6氇呾棎瓴� 381,000欤检棎 雽�頃� 鞀ろ啞鞓奠厴鞚� 攵�鞐枅鞀惦媹雼�.
頄夓偓臧赌瓴╈潃 欤茧嫻 $1.72鞚措┌, 鞓奠厴鞚� 4雲勱皠 氩犾姢韺呺惄雼堧嫟: 觳暣鞐� 25% 氩犾姢韸�霅橁碃 雮橂ǜ歆� 75%電� 鞚错泟 3雲� 霃欖晥 毵れ洈 氩犾姢韺�霅╇媹雼�. 鞚� 攵�鞐姅 氤挫儊鞙勳洂須� 鞀轨澑 頃橃棎 Nasdaq Listing Rule 5635(c)(4)毳� 欷�靾橅晿氅�, 鞁犼窚 鞚胳灛 鞙犾箻毳� 氇╉憸搿� 頃╇媹雼�.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), une soci茅t茅 biopharmaceutique en phase clinique ax茅e sur le d茅veloppement d鈥檜n inhibiteur de WEE1 pour le traitement du cancer de l鈥檕vaire, a annonc茅 des attributions d鈥檌nducement dans le cadre de son 2022 Employment Inducement Incentive Award Plan. La soci茅t茅 a accord茅 des options sur 381 000 actions 脿 six nouveaux employ茅s.
Les options, au prix d鈥檈xercice de 1,72 $ par action, seront acquises sur quatre ans : 25 % seront acquis la premi猫re ann茅e et les 75 % restants seront acquis mensuellement sur les trois ann茅es suivantes. Ces attributions, approuv茅es par le Compensation Committee et conformes 脿 la Nasdaq Listing Rule 5635(c)(4), visent 脿 attirer de nouveaux talents.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), ein biopharmazeutisches Unternehmen in klinischer Phase, das an einem WEE1-Inhibitor zur Behandlung von Eierstockkrebs arbeitet, hat Inducement-Grants im Rahmen seines 2022 Employment Inducement Incentive Award Plan angek眉ndigt. Das Unternehmen gew盲hrte sechs neuen Mitarbeitenden Aktienoptionen auf 381.000 Aktien.
Die Optionen haben einen Aus眉bungspreis von $1,72 pro Aktie und werden 眉ber vier Jahre unverfallbar: 25% werden im ersten Jahr unverfallbar, die restlichen 75% unverfallen monatlich 眉ber die folgenden drei Jahre. Die Zuweisungen wurden vom Compensation Committee genehmigt, entsprechen der Nasdaq Listing Rule 5635(c)(4) und sollen neues Talent anziehen.
- None.
- None.
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis庐 Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on September 2, 2025, the Compensation Committee of Zentalis鈥� Board of Directors granted non-qualified stock options to purchase an aggregate of 381,000 shares of the Company鈥檚 common stock to six (6) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual鈥檚 entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual鈥檚 entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
Vesting of the stock options is subject to the employee鈥檚 continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis庐 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit . Follow Zentalis on LinkedIn at .
ZENTALIS庐聽and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
Contacts:
Aron Feingold 鈥� VP, IR & Corp Comms
FAQ
What stock options did Zentalis Pharmaceuticals (ZNTL) grant to new employees in September 2025?
What is the vesting schedule for Zentalis (ZNTL) employee stock options granted in September 2025?
What is Zentalis Pharmaceuticals' (ZNTL) main drug development focus?
What is the purpose of Zentalis' (ZNTL) 2022 Inducement Plan?
